IMCD (IMCD) Q2 2024 earnings summary

Executive summary

• Revenue for H1 2024 reached €2.385 billion, up 4% year-over-year, driven by acquisitions despite a 4% organic decline.

• Gross profit rose 4% to €607 million (+5% constant currency), with operating EBITDA/EBITA at €270 million, reflecting a 2% decrease on a constant currency basis versus H1 2023, mainly due to a weak Q1.

• Net result for the period was €141 million, down 7% year-over-year, with cash EPS at €3.23.

• Eleven acquisitions were completed year-to-date, expanding presence in key markets and adding approximately €250 million in revenue and 360 employees.

• Life sciences and industrials contributed significantly to revenue, with personal care (excluding China) and coatings/construction performing well.

Financial highlights

• Gross profit margin remained stable at 25.4%, with Q1 and Q2 margins nearly identical.

• Operating EBITDA/EBITA margin declined to 11.3% from 12.2% in H1 2023.

• Free cash flow for H1 was €221 million, down from €241 million in H1 2023.

• Cash earnings per share were €3.23, slightly lower than €3.28 a year earlier.

• Net debt increased to €1.59 billion, with a leverage ratio of 2.9x EBITDA.

Outlook and guidance

• Management remains confident in delivering further growth and efficiencies through investments in digital, commercial excellence, and operational improvements, but refrains from providing quantitative guidance due to ongoing macroeconomic and political uncertainty.

• Market volatility persists, with little visibility beyond six weeks due to customer inventory strategies and political instability.

• Opportunities exist for further global expansion both organically and via acquisitions.